GE HealthCare Technologies Inc, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier, has completed its acquisition of the remaining 50 per cent stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership.
As part of GE HealthCare, Nihon Medi-Physics can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.
Kevin O’Neill, president & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become president of Nihon Medi-Physics, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market1 and a center of excellence for Asian markets. As part of GE HealthCare, Nihon Medi-Physics will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”
Nihon Medi-Physics’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. Nihon Medi-Physics, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP.
As part of GE HealthCare, Nihon Medi-Physics, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease.